ARTICLE | Company News
Onxeo, University of Navarra deal
February 29, 2016 8:00 AM UTC
The university will conduct preclinical trials evaluating Onxeo’s Beleodaq belinostat and Livatag doxorubicin in combination with immuno-oncology compounds, including PD-1 and CTLA-4 (CD152) inhib...